Anti‐tumour necrosis factor therapy enhances mucosal healing through down‐regulation of interleukin‐21 expression and T helper type 17 cell infiltration in C rohn's disease
Author(s) -
Liu C.,
Xia X.,
Wu W.,
Wu R.,
Tang M.,
Chen T.,
Xu F.,
Cong Y.,
Xu X.,
Liu Z.
Publication year - 2013
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.12084
Subject(s) - rar related orphan receptor gamma , lamina propria , medicine , tumor necrosis factor alpha , infliximab , interleukin 17 , intestinal mucosa , cytokine , immunology , t helper cell , interleukin , t cell , pathology , foxp3 , immune system , epithelium
Summary Anti‐tumour necrosis factor ( TNF ) monoclonal antibody ( mAb ) (infliximab, IFX ) has been shown to be highly effective in the management of C rohn's disease ( CD ). Herein we investigated the potential role of IFX in inducing clinical remission and regulating interleukin ( IL )‐21 expression and T helper type 17 ( Th 17) cell infiltration in the intestinal mucosa of CD patients. Twenty‐six CD patients were treated with IFX at weeks 0, 2 and 6. Clinical response, mucosal healing, serum C ‐reactive protein ( C RP ) and erythrocyte sedimentation rate ( ESR ) were evaluated at week 10 after IFX administration. Expression of IL ‐21, IL ‐17A and retinoic acid‐related orphan receptor C ( RORC ) in intestinal mucosa were analysed by quantitative real‐time polymerase chain reaction ( PCR ) and immunohistochemistry. Peripheral blood and lamina propria CD 4 + T cells were stimulated with anti‐ CD 3 and anti‐ CD 28 mAbs in the presence of I FX . Cytokine profiles and RORC were determined with enzyme‐linked immunosorbent assay ( ELISA ) and real‐time PCR . IL ‐21 and Th 17 cells were found to be expressed highly in inflamed mucosa of active CD patients compared with healthy controls. Ten weeks after IFX infusion, C D activity index, ESR , CRP and intestinal mucosal healing were improved markedly in CD patients, and IL ‐21 expression and Th 17 cell infiltration were decreased significantly compared with those before IFX therapy. In‐vitro study demonstrated that IFX treatment could suppress IL ‐21, IL ‐17 A and RORC expression in cultured CD biopsies. Moreover, IFX was also observed to down‐regulate markedly IL ‐17A, IL ‐21 and RORC expression by CD CD 4 + T cells. IFX is highly effective in inducing clinical remission and promoting intestinal mucosal healing in CD patients through down‐regulation of IL ‐21 expression and Th 17 cell infiltration in intestinal mucosa.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom